Retapamulin CAS# 224452-66-8 瑞他莫林
Retapamulin, also known as SB-275833, is a newer topical agent of pleuromutilin class approved by the Food and Drug Administration for treatment of impetigo in children. It has been demonstrated to have low potential for the development of antibacterial resistance and a high degree of potency against poly drug resistant Gram-positive bacteria found in skin infections including Staphylococcus aureus strains. The drug is safe owing to low systemic absorption and has only minimal side-effect of local irritation at the site of application.
📌 参考资料/链接：
Breen, Gary Francis; Forth, Michael Anthony; Kopelman, Susan Shumei Hu; Muller, Francis Xavier; Sanderson, Francis Dominic. Process for preparation of mutilin derivatives and their salts as antibacterial agents. Assignee Glaxo Group Limited, UK. WO 2005023257. (2005).
Breen, Gary Francis; Forth, Michael Anthony; Kopelman, Susan Shumei Hu; Muller, Francis Xavier; Sanderson, Francis Dominic. Process for preparation of mutilin derivatives and their salts as antibacterial agents. Assignee Glaxo Group Limited, UK. WO 2005023257. (2005).
📄 详细内容
CAS No. 224452-66-8 瑞他莫林Retapamulin synthetic routes
Breen, Gary Francis; Forth, Michael Anthony; Kopelman, Susan Shumei Hu; Muller, Francis Xavier; Sanderson, Francis Dominic. Process for preparation of mutilin derivatives and their salts as antibacterial agents. Assignee Glaxo Group Limited, UK. WO 2005023257. (2005).
产品链接: CAS No. 224452-66-8 ››
Breen, Gary Francis; Forth, Michael Anthony; Kopelman, Susan Shumei Hu; Muller, Francis Xavier; Sanderson, Francis Dominic. Process for preparation of mutilin derivatives and their salts as antibacterial agents. Assignee Glaxo Group Limited, UK. WO 2005023257. (2005).
产品链接: CAS No. 224452-66-8 ››